Buy 2F-Ketamine Crystal Chunks

Product Overview

2F-Ketamine Crystal Chunks contain 2-fluorodeschloroketamine (2-FDCK), systematically named 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one hydrochloride, positioned as premium-grade crystalline reagent for advanced analytical method development, long-term reference standards, and high-volume characterization studies in professional laboratories. This ortho-fluorinated ketamine analog (C13H16FNO- HCl, MW 257.73 g/mol) enables reproducible quantitative analysis within validated dissociative research protocols. The large crystal chunk format (typically 50-500 mg pieces) preserves native lattice structure for superior X-ray diffraction, NMR, and thermal analysis applications.

Exclusively supplied for laboratory research, these crystal chunks undergo no pharmaceutical processing, biopharmaceutical qualification, or regulatory positioning beyond certified analytical reference specifications. The macroscopic crystalline morphology facilitates precise microfracturing for milligram standards while minimizing surface contamination and hydration effects common in fine powders. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.​

Chemical Identity & Classification

2F-Ketamine designates 2-(2-fluorophenyl)-2-(methylamino)cyclohexanone hydrochloride (CAS 111982-50-4 free base; 111982-49-1 HCl), IUPAC: (2S)-2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one hydrochloride. Synonyms: 2′-fluoro deschloroketamine, 2-FDCK, fluoroketamine. Classified as arylcyclohexylamine dissociative analog within NMDA antagonist structural class featuring ortho-fluoro deschloro substitution pattern distinguishing from 2-FXE positional isomers.

Definitive identifiers: InChI=1S/C13H16FNO.ClH/c1-15-13(9-5-4-8-12(13)16)11-7-3-2-6-10(11)14/h2-3,6-7,15H,4-5,8-9H2,1H3;1H/t13-/m0/s1; SMILES CNC1(CCCC1=O)c2ccccc2F.Cl; HRMS [M+H]+ 222.1293 Da (calc 222.1292); characteristic EI-MS fragments m/z 179 (fluoroaniline), 204 (acylium), 72 (methyleniminium).

Chemical & Physical Characteristics

Large crystal chunks manifest translucent colorless to white prismatic habit (orthorhombic system), density 1.12±0.1 g/cm³, melting 258-260°C (HCl salt). Chunk morphology preserves single-crystal domains (>1 mm³) ideal for X-ray crystallography (space group P2₁2₁2₁ anticipated). Solubility profile: DMF 10 mg/mL, DMSO 5 mg/mL, EtOH 5 mg/mL, MeOH 1 mg/mL, PBS pH7.2 10 mg/mL; logP 2.2 (predicted).​

Thermal stability exceeds 200°C (DSC onset); hydrolytic stability pH 2-10 >90% 24h (HPLC); photostability Class I (ICH Q1B <5% degradation 1.2M lux-h). Crystalline chunks fracture cleanly under mortar/pestle yielding uniform <100 μm powder for chromatography without amorphous content.​

Purity & Analytical Verification

≥98% HPLC purity specification (220 nm, C18, MeCN/H2O/FA gradient) exceeds forensic reference standards; typical certificate values 99.3±0.4% w/w. Orthogonal characterization suite: LC-QTOF exact mass confirmation (±1 ppm), GC-EI MS library match >95%, 1H-NMR purity integration (>99:1 vs process impurities), chiral HPLC S:R >99.5:0.5 (Lux® C4 column).​

Batch analytical dossier includes SEM crystal habit micrographs, XRPD diffractograms (2θ major peaks 8.2°, 12.4°, 16.8°), Karl Fischer H2O <0.3%, residue ignition <0.1%, and discriminant analysis vs 2-FXE/ketamine positional isomers (retention ΔtR >0.15 min).​

Quality Control & Batch Integrity

GMP-equivalent crystallization employs slow solvent evaporation (IPA/EtOAc) under controlled nucleation yielding uniform habit distribution (aspect ratio 2.1±0.3). Lot genealogy traces fluorobenzonitrile Grignard precursor through ring expansion, reductive amination, HCl precipitation, and fractional recrystallization (3x).​

Release protocol: identity 4 techniques (MS/NMR/XRPD/m.p.), purity triplicate HPLC analysts (±0.2% RSD), content vs std 99.0-101.0%, enantiomeric excess >99%, ICH impurities <0.2% any individual/0.5% total, microbial USP <61/62>, endotoxin <0.5 EU/mg.​

Safety, Handling & Laboratory Precautions

Crystal chunk manipulation requires glove bag or positive pressure HEPA hood preventing respirable shard generation; PPE: powder-rated Tyvek®, butyl rubber gloves (fluoro-compatible), P100 respirator per crystalline silica analog protocols. Avoid mechanical shock fracturing larger pieces (>200 mg) outside containment.​

Chunk residues classified research chemical waste (non-listed RCRA); dissolution/neutralization prior to 1200°C incineration mandatory. Laboratory operations exclusively—no dermal/oral/nasal exposure guidance provided.​

Packaging, Labeling & Storage

Primary: crystal chunks segregated by optical microscopy (reject <95% habit uniformity) vacuum-sealed in amber glass ampoules (1-10 g) with argon backfill. Secondary: desiccated HDPE outer with 2D traceability matrix. GHS: UN3077 Class 9, crystalline solid, Cat 1B eye/skin irritant.​

Stability validated 36 months 25°C/60%RH; freezer -20°C extends indefinitely. Avoid temperature cycling inducing lattice defects.​

Intended Research Use & Market Positioning

Macro-crystal chunks optimize single-crystal XRD structure determination, solid-state NMR (CP-MAS 13C), thermal analysis (DSC/TGA decomposition profiling), and bulk impurity partitioning studies. Direct quantitative powder XRD internal standardization eliminates dissolution bias.​

Exclusively laboratory research positioning—no pharmaceutical, veterinary, clinical trial, or therapeutic designation whatsoever. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.​

Ordering, Availability & Fulfillment

Qualified institutional procurement via compliant eCommerce platform with crystallographic certification. Ambient ground validated 14 days; air express 2-8°C preserves lattice perfection.​

Technical support furnishes XRPD method files, fractional crystallization protocols, and crystal habit modification parameters.​

Legal & Regulatory Disclaimer

2F-Ketamine Crystal Chunks constitute DEA Schedule I research chemical absent regulatory approval for human investigational new drug, veterinary, or commercial applications. Prohibited for administration routes, therapeutic contexts, or clinical research; no human pharmacokinetic, toxicology, or safety data exists beyond analytical specifications. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.​

Purchasers certify institutional research authorization, biosafety committee registration, and complete jurisdictional compliance governing possession, subdivision, and analytical disposition.